Please try another search
The fund is a non-UCITS fund, whereby the fund may concentrate holdings to a smaller number of companies than what is applicable to UCITS funds. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca and may also invest in other equities issued by companies with a connection to Sweden and the rest of the Nordics. The fund is a special fund (non-UCITS) that may invest in the following types of assets: - a) in transferable securities issued by companies in Sweden or that are admitted to or the subject of trading in Sweden and b) in transferable securities issued by companies in the Nordics or that are admitted to or the subject of trading in the Nordics, - in money market instruments, - in derivative instruments, - in fund units (to a maximum of 10% of the fund’s value), and - in an account at a credit institution.
Name | Title | Since | Until |
---|---|---|---|
Yvonne Sörberg | - | 2022 | Now |
Jens Melander | - | 2020 | 2022 |
Yvonne Sörberg | - | 2019 | 2020 |
Jonathan Schönbäck | - | 2013 | 2019 |
Lars Johansson | - | 2007 | 2013 |
Biography | Civilekonom, Handelshögskolan Umeå |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review